He joins the US biotech from private investment firm Colchester Healthcare Investments" /> He joins the US biotech from private investment firm Colchester Healthcare Investments" />

Please login to the form below

Not currently logged in
Email:
Password:

Ischemix names David DeWahl as CEO

He joins the US biotech from private investment firm Colchester Healthcare Investments

David DeWahl has been appointed president and CEO of US biotech Ischemix.

He joins after stepping down from his role as president of private investment firm Colchester Healthcare Investments.

He has also previously served as VP corporate development at Helix Therapeutics and managing director at Life Science Group – a company he co-founded.

Prior to that, DeWahl was an investment banker with a focus on healthcare the life sciences.

“His background in building life sciences companies and his experience in developing corporate collaborations in the industry and in raising capital will substantially strengthen Ischemix as we continue the clinical development of our drug candidates,” said Dr Reinier Beeuwkes, chairman of the board and chief scientific officer at Ischemix.

These candidates include the company's lead compound CMX-2043, which is being developed to protect against heart and kidney damage due to the interruption of blood flow.

The investigational drug has recently demonstrated positive benefits in phase IIa trials, and further development is expected this year.

11th January 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics